Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts.
Tatsuki UemuraShingo ItoTakeshi MasudaHiroko ShimboTomohide GotoHitoshi OsakaTakahito WadaPierre-Olivier CouraudSumio OhtsukiPublished in: Pharmaceutical research (2020)
The present study suggests that cyclocreatine is a CRT substrate, where CRT is the predominant contributor to influx of cyclocreatine into the brain at the BBB. Our findings provide vital insights for the purposes of treating CCDSs patients using cyclocreatine.
Keyphrases
- blood brain barrier
- end stage renal disease
- cerebral ischemia
- endothelial cells
- chronic kidney disease
- newly diagnosed
- induced apoptosis
- cardiac resynchronization therapy
- peritoneal dialysis
- prognostic factors
- cell therapy
- multiple sclerosis
- induced pluripotent stem cells
- cell proliferation
- cell death
- extracellular matrix
- atrial fibrillation